Under bankruptcy, owners and financials
CVR: 39308967
Previous names: Integrated biomedical technologies ApS, IBIO TECH ApS
DKK 2,442
Gross profit
Net result: DKK -131,289
Tue Wenzel Kragstrup (15-19,99%), Peter Andreas Nicolai Reumert Wagtmann (10-14,99%)
3 more
CVR · view owners
No management registered
CVR · view management
Under bankruptcy
Founded 5 February 2018
CVR · view overview
1 employee
CVR · 2025
Director role ended: Kira Gerber Petersen
CVR · 28/04/2026
View the full event history
Aptol Pharma ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include Tue Wenzel Kragstrup, Peter Andreas Nicolai Reumert Wagtmann and ADT HOLDING ApS. The company has 1 employee (2025). In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity in the 2024 report amounted to DKK -140,336.
Selskabets formål er at udvikle nye lægemidler alene eller i partnerskaber.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202401/01/2024 – 31/12/2024 | - | -131 t. | 48 t. | -140 t. | 1 | |
| 202301/01/2023 – 31/12/2023 | - | 308 t. | 163 t. | -9 t. | 1 | |
| 202201/01/2022 – 31/12/2022 | - | -334 t. | 104 t. | -317 t. | - | |
| 202101/01/2021 – 31/12/2021 | 0 | 0 | 50 t. | 50 t. | - | |
| 202001/01/2020 – 31/12/2020 | 0 | -2 t. | 50 t. | 50 t. | - | |
| 201901/01/2019 – 31/12/2019 | 0 | -2 t. | 50 t. | 50 t. | - | |
| 201805/02/2018 – 31/12/2018 | 0 | 129 t. | 75 t. | 50 t. | - |
Compared to 1.039 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Indkaldelse til fordringsprøvelse i konkursboet Aptol Pharma ApS, Sø- og Handelsretten, sagsnr. K 847/26-K.
Ved dekret af 28. april 2026 har Sø- og Handelsrettens skifteret taget Aptol Pharma ApS under konkursbehandling. Kurator: Advokat Jacob Smith, August Bournonvilles Passage 1, 1055 København K. Sagsnr. K 847/26-K.
Source: Statstidende, updated daily
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreYes. Aptol Pharma ApS is registered in the Danish CVR register with the status under bankruptcy. The bankruptcy decree is published in Statstidende.
The CVR number of Aptol Pharma ApS is 39308967.
The owners of Aptol Pharma ApS include Tue Wenzel Kragstrup, Peter Andreas Nicolai Reumert Wagtmann and ADT HOLDING ApS.
In 2024, Aptol Pharma ApS reported a gross profit of DKK 2,442.
Aptol Pharma ApS had 1 employee in 2025 according to the Danish CVR register.
Aptol Pharma ApS was founded on 5 February 2018.
Contact info changed: new phone: 26784520, new email: [email protected], new website: aptolpharma.com (September 20, 2026).
On September 20, 2026, Aptol Pharma ApS was placed under bankruptcy proceedings.
On September 18, 2026, a notice regarding Aptol Pharma ApS was published in Statstidende: Indkaldelse til fordringsprøvelse (S16092026-234).
Contact info changed: new phone: 26784520, new email: [email protected], new website: aptolpharma.com (May 2, 2026).
On April 30, 2026, a notice regarding Aptol Pharma ApS was published in Statstidende: Konkursdekret (S28042026-218).
As of April 28, 2026, Kira Gerber Petersen has left the board of directors of Aptol Pharma ApS.
As of April 28, 2026, Peter Andreas Nicolai Reumert Wagtmann has left the board of directors of Aptol Pharma ApS.
As of April 28, 2026, Kira Gerber Petersen has stepped down as director of Aptol Pharma ApS.
As of November 28, 2025, Mads Hartvig Clausen has left the board of directors of Aptol Pharma ApS.
As of November 28, 2025, Peter Andreas Nicolai Reumert Wagtmann is registered as an owner of Aptol Pharma ApS with an ownership share of 10%.
As of November 28, 2025, ADT HOLDING ApS is registered as an owner of Aptol Pharma ApS with an ownership share of 10%.
As of September 1, 2025, KGAA Holding ApS is registered as an owner of Aptol Pharma ApS with an ownership share of 33%.
As of July 31, 2025, Mads Hartvig Clausen has joined the board of directors of Aptol Pharma ApS.
As of July 31, 2025, Anders Dyhr Dombernowsky-Toft has left the board of directors of Aptol Pharma ApS.
As of July 30, 2025, Mads Hartvig Clausen has left the board of directors of Aptol Pharma ApS.
As of February 28, 2025, Tue Wenzel Kragstrup is registered as an owner of Aptol Pharma ApS with an ownership share of 15%.
As of February 28, 2025, is registered as an owner of Aptol Pharma ApS with an ownership share of 15%.
Aptol Pharma ApS has published its annual report for 2024. Gross profit came to DKK 2,442, and the net result was DKK -131,289.
As of February 16, 2024, Mads Hartvig Clausen has joined the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2023. Gross profit came to DKK 414,462, and the net result was DKK 307,979.
As of October 27, 2023, Peter Andreas Nicolai Reumert Wagtmann has joined the board of directors of Aptol Pharma ApS.
As of August 21, 2023, Anders Dyhr Dombernowsky-Toft has joined the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2022. Gross profit came to DKK -421,544, and the net result was DKK -334,362.
On May 25, 2022, the company changed its name from IBIO TECH ApS to Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK 0.
Aptol Pharma ApS has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -2,464.
Aptol Pharma ApS has published its annual report for 2019. Revenue came to DKK 0, and the net result was DKK -2,348.
As of December 13, 2019, Kira Gerber Petersen has joined the board of directors of Aptol Pharma ApS.
On December 13, 2019, the company changed its name from Integrated biomedical technologies ApS to IBIO TECH ApS.
As of December 12, 2019, Kira Gerber Petersen has left the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its interim report for the period February 5, 2018 to December 31, 2018.
As of February 5, 2018, Kira Gerber Petersen has joined the board of directors of Aptol Pharma ApS.
As of February 5, 2018, Kira Gerber Petersen is registered as director of Aptol Pharma ApS.
Aptol Pharma ApS was founded on February 5, 2018.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 19352102
CVR 44931885
CVR 44214032
CVR 46763904
CVR 46354834
